Testing tunlametinib for NRAS-mutant solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental pill (Tunlametinib) for people with solid tumors that have a specific NRAS gene change and have stopped responding to other treatments. The goal is to see if the drug can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific change in the NRAS gene (called an NRAS mutation).
- You cannot have had any other cancer (except minor skin cancers) in the last 2 years.
- You cannot have a buildup of fluid in your chest, heart area, or belly that needs frequent draining.
- You must not have serious heart problems, like an irregular heartbeat or recent heart attack.
- You cannot have an active hepatitis B or C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called Tunlametinib (a MEK inhibitor) compared to standard chemotherapy for people with advanced melanoma that has a specific NRAS gene change and no longer responds to immunotherapy. It aims to see if the new pill works better or is safer than chemo.
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
This trial tests a new oral targeted therapy (Tunlametinib) for people with advanced melanoma that has a specific gene change called NRAS. It's for those who have already tried immunotherapy and need another option.
This trial tests a targeted drug (tunlametinib) for advanced thyroid cancer that has a specific genetic change called NRAS mutation. It may help people whose cancer is not responding to standard treatments like radioactive iodine.
This trial tests a combination of two targeted drugs (Tunlametinib and an anti-EGFR antibody) in people with advanced pancreatic or colorectal cancer that has a RAS mutation and has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination treatment with tunlametinib for people with a specific type of advanced non-small cell lung cancer (NSCLC) that has a KRAS mutation and has not responded to standard therapy. The goal is to see if this targeted therapy can help shrink or slow the cancer.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.